Nearly 4 billion people around the world live with correctable vision problems like myopia (nearsightedness) and presbyopia (“aging eyes” that require reading glasses). To put things into focus (literally), we’re spending $48 billion every year on glasses, $16 billion on contacts, and $6 billion on corrective surgeries.

One of the most popular elective surgeries of the past twenty years has been LASIK. Yet unintended complications such as dry eyes or night halos have led to less-than-stellar patient reviews. In developed markets like the United States, the number of LASIK procedures taking place per year are only half of what they were 15 years ago.

Is there a better option available?

7investing Lead Advisor Simon Erickson’s Top Stock for September 2021 is a niche market leader who is addressing several of the world’s eyesight issues. Its disruptive new solution is gaining share in several international markets, and there are two clear catalysts on the horizon that could greatly benefit investors.